ML-228 manufacturers
- ML228
-
- $37.00
-
2026-06-02
- CAS:1357171-62-0
- Purity: 99.54%
- Supply Ability: 10g
|
| Product Name: | ML-228 | | Synonyms: | ML-228;N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine;ML228; ML 228;N-([1,1'Biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine;CID-46742353;ML-228;CID-46742353;L-228;1,2,4-Triazin-5-amine, N-([1,1'-biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)- | | CAS: | 1357171-62-0 | | MF: | C27H21N5 | | MW: | 415.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1357171-62-0.mol |  |
| | ML-228 Chemical Properties |
| Boiling point | 686.0±65.0 °C(Predicted) | | density | 1.228±0.06 g/cm3(Predicted) | | storage temp. | -20°C, Inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 2.03±0.63(Predicted) | | color | Pale Yellow to Light Yellow |
| | ML-228 Usage And Synthesis |
| Uses | N-([1,1''-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine is an activator of the hypoxia inducible factor (HIF) pathway. | | Definition | ChEBI: ML228 is a member of the class of 1,2,4-triazines in which the triazine ring is substituted at positions 3, 5, and 6 by pyridin-2-yl, ([biphenyl]-4-ylmethyl)amin, and methyl groups, respectively. It is an activator of the hypoxia inducible factor (HIF) pathway. It has a role as a hypoxia-inducible factor pathway activator. It is a member of biphenyls, a member of 1,2,4-triazines, a secondary amino compound and a member of pyridines. | | in vivo | ML228 (injection; 1 μg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function[3]. | Animal Model: | SD rat[3] | | Dosage: | 1 μg/kg | | Administration: | injection; 7 days | | Result: | Alleviated SCI of the central nervous system and relieve associated symptoms. |
|
| | ML-228 Preparation Products And Raw materials |
|